Skip To Main Content
Lilly
Menu closed
Lilly
  • Account Login / Register
  • Medical Home
    • Medical Information
      • All Events
      • COVID-19
      • Diabetes
      • Immunology
      • Neuroscience
      • Obesity
      • Oncology
      • Cardiovascular
      • COVID-19
      • Diabetes
      • Immunology
      • Men's Health
      • Neuroscience
      • Oncology
  • Medical Education
Ask Lilly

We're here to help.

Chat
Chat with us Chat with us
Question Contact Us
Expand contact lilly
Lilly

You are now leaving the LillyMedical.com website

The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to LillyMedical.com.

Immunology Journal Publications

This page includes links to Lilly sponsored clinical trials that have been published in peer reviewed journals over the last 3 years. The list of publications below is limited to products that have been approved for use and may contain information about doses, delivery devices, uses, formulations and populations different from product labeling. Clinical decisions should be based on the full safety and efficacy information contained in the product's Full Prescribing Information in the provided link below.

If you have questions about a Lilly study not listed below or would like to request an electronic copy of one of the journal publications on this page, please Contact Lilly services below for further assistance.

Olumiant

Full Prescribing Information

Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis

Published Date: January 22, 2019
Publication Link

Prediction of Transporter-Mediated Drug-Drug Interactions for Baricitinib

Published Date: July 27, 2017
Publication Link

Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical Trials

Published Date: April 7, 2021
Publication Link   |   Video Abstract Link

Safety of baricitinib in East Asian patients with moderate-to-severe active rheumatoid arthritis: An integrated analysis from clinical trials

Published Date: November 14, 2019
Publication Link

Baricitinib for systemic lupus erythematosus – Authors' reply

Published Date: February 2, 2019
Publication Link

Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis

Published Date: January 22, 2019
Publication Link

MRI and Dose Selection in a Phase II Trial of Baricitinib with Conventional Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis

Published Date: January 15, 2019
Publication Link

Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial

Published Date: July 21, 2018
Publication Link

JAK1/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a Phase 2 randomized controlled clinical trial

Published Date: February 22, 2018
Publication Link

Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study

Published Date: February 1, 2018
Publication Link

Safety and Efficacy of Baricitinib Through 128 Weeks in an Open-label, Longterm Extension Study in Patients with Rheumatoid Arthritis

Published Date: August 15, 2017
Publication Link

Efficacy and safety of baricitinib in Japanese patients with active rheumatoid arthritis: A 52-week, randomized, single-blind, extension study

Published Date: April 25, 2017
Publication Link

Two Phase 3 Trials of Baricitinib for Alopecia Areata

Published Date: March 26, 2022
Publication Link

Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical Trials

Published Date: April 7, 2021
Publication Link   |   Video Abstract Link

Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis

Published Date: February 25, 2020
Publication Link

Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials

Published Date: January 29, 2020
Publication Link

Safety of baricitinib in East Asian patients with moderate-to-severe active rheumatoid arthritis: An integrated analysis from clinical trials

Published Date: November 14, 2019
Publication Link

Effect of Baricitinib and Adalimumab in Reducing Pain and Improving Function in Patients with Rheumatoid Arthritis in Low Disease Activity: Exploratory Analyses from RA-BEAM

Published Date: September 5, 2019
Publication Link

Efficacy and safety of long-term baricitinib with and without methotrexate for the treatment of rheumatoid arthritis: experience with baricitinib monotherapy continuation or after switching from methotrexate monotherapy or baricitinib plus methotrexate

Published Date: June 24, 2019
Publication Link

Relative Impact of Pain and Fatigue on Work Productivity in Patients with Rheumatoid Arthritis from the RA-BEAM Baricitinib Trial

Published Date: June 21, 2019
Publication Link

Achieving Pain Control in Rheumatoid Arthritis with Baricitinib or Adalimumab Plus Methotrexate: Results from the RA-BEAM Trial

Published Date: June 12, 2019
Publication Link

Cost-effectiveness analysis of baricitinib versus adalimumab for the treatment of moderate-to-severe rheumatoid arthritis in Spain

Published Date: June 6, 2019
Publication Link

Low rates of radiographic progression of structural joint damage over 2 years of baricitinib treatment in patients with rheumatoid arthritis

Published Date: May 10, 2019
Publication Link

Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis

Published Date: May 1, 2019
Publication Link

Evaluation of pneumococcal and tetanus vaccine responses in patients with rheumatoid arthritis receiving baricitinib: results from a long-term extension trial substudy

Published Date: April 19, 2019
Publication Link

Use of daily electronic patient-reported outcome (PRO) diaries in randomized controlled trials for rheumatoid arthritis: rationale and implementation

Published Date: March 22, 2019
Publication Link

Efficacy and safety data based on historical or pre-existing conditions at baseline for patients with active rheumatoid arthritis who were treated with baricitinib

Published Date: March 8, 2019
Publication Link

Safety profile of baricitinib in Japanese patients with active rheumatoid arthritis with over 1.6 years median time in treatment: An integrated analysis of Phases 2 and 3 trials

Published Date: February 20, 2019
Publication Link

Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis

Published Date: January 22, 2019
Publication Link

Safety and Efficacy of Baricitinib in Patients Receiving Conventional Synthetic Disease-Modifying Antirheumatic Drugs or Corticosteroids

Published Date: October 24, 2018
Publication Link

Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment

Published Date: September 15, 2018
Publication Link

Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study

Published Date: September 7, 2018
Publication Link

Structural damage progression in patients with early rheumatoid arthritis treated with methotrexate, baricitinib, or baricitinib plus methotrexate based on clinical response in the phase 3 RA-BEGIN study

Published Date: August 4, 2018
Publication Link

Characterization and Changes of Lymphocyte Subsets in Baricitinib-Treated Patients With Rheumatoid Arthritis

Published Date: July 29, 2018
Publication Link

Mean cost per number needed to treat of baricitinib versus adalimumab in the treatment of rheumatoid arthritis in Italy>

Published Date: July 27, 2018
Publication Link

Effects of baricitinib on radiographic progression of structural joint damage at 1 year in patients with rheumatoid arthritis and an inadequate response to conventional synthetic disease-modifying antirheumatic drugs

Published Date: May 8, 2018
Publication Link

Baricitinib in Patients with Rheumatoid Arthritis and an Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs in United States and Rest of World: A Subset Analysis

Published Date: April 21, 2018
Publication Link

Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies

Published Date: February 23, 2018
Publication Link

Determinants of Patient’s Global Assessment of Disease Activity and Physician’s Global Assessment of Disease Activity in patients with rheumatoid arthritis: A post hoc analysis of overall and Japanese results from phase 3 clinical trials

Published Date: February 9, 2018
Publication Link

Relationship between disease activity and patient-reported outcomes in rheumatoid arthritis: Post hoc analyses of overall and Japanese results from two phase 3 clinical trials

Published Date: February 9, 2018
Publication Link

Response to baricitinib based on prior biologic use in patients with refractory rheumatoid arthritis

Published Date: February 3, 2018
Publication Link

Response to baricitinib therapy in patients with rheumatoid arthritis with inadequate response to csDMARDs as a function of baseline characteristics

Published Date: January 13, 2018
Publication Link

Psychometric properties of morning joint stiffness duration and severity measures in patients with moderately to severely active rheumatoid arthritis

Published Date: December 6, 2017
Publicatdion Link

Psychometric properties of the single-item measure, severity of worst tiredness, in patients with moderately to severely active rheumatoid arthritis

Published Date: December 6, 2017
Publication Link

Efficacy and safety of baricitinib in Japanese patients with rheumatoid arthritis: Subgroup analyses of four multinational phase 3 randomized trials

Published Date: November 14, 2017
Publication Link

Safety and efficacy of baricitinib in elderly patients with rheumatoid arthritis

Published Date: October 11, 2017
Publication Link

Dose/Exposure-Response Modeling to Support Dosing Recommendation for Phase III Development of Baricitinib in Patients with Rheumatoid Arthritis

Published Date: September 29, 2017
Publication Link

Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment

Published Date: September 18, 2017
Publication Link

Patient-reported outcomes from a phase III study of baricitinib in patients with conventional synthetic DMARD-refractory rheumatoid arthritis

Published Date: March 21, 2017
Publication Link

Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis

Published Date: February 16, 2017
Publication Link

No Publication Journals

Taltz

Full Prescribing Information

Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure

Published Date: November 20, 2019
Publication Link

Prevalence and outcome of latent tuberculosis in patients receiving ixekizumab: integrated safety analysis from 11 clinical trials of patients with plaque psoriasis

Published Date: January 4, 2019
Publication Link

Long-term safety profile of ixekizumab in patients with moderate-to-severe plaque psoriasis: an integrated analysis from 11 clinical trials

Published Date: September 10, 2018
Publication Link

Response to Tetanus and Pneumococcal Vaccination Following Administration of Ixekizumab in Healthy Participants

Published Date: December 1, 2017
Publication Link

Infections from seven clinical trials of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriasis

Published Date: November 17, 2017
Publication Link

Prevalence and outcome of latent tuberculosis in patients receiving ixekizumab: integrated safety analysis from 11 clinical trials of patients with plaque psoriasis

Published Date: January 4, 2019
Publication Link

Long-term safety profile of ixekizumab in patients with moderate-to-severe plaque psoriasis: an integrated analysis from 11 clinical trials

Published Date: September 10, 2018
Publication Link

Efficacy and safety of ixekizumab over 4 years of open-label treatment in a phase 2 study in chronic plaque psoriasis

Published Date: April 11, 2018
Publication Link

Infections from seven clinical trials of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriasis

Published Date: November 17, 2017
Publication Link

A subset analysis of efficacy and safety outcomes from phase 3 clinical studies of ixekizumab for the treatment of patients with severe plaque psoriasis

Published Date: April 21, 2020
Publication Link

Efficacious psoriasis treatment improves patients' work productivity

Published Date: April 11, 2020
Publication Link

Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials

Published Date: March 21, 2020
Publication Link

Ixekizumab treatment of biologic-naïve patients with active psoriatic arthritis: 3-year results from a phase III clinical trial (SPIRIT-P1)

Published Date: February 7, 2020
Publication Link

Safety results of ixekizumab with 1822.2 patient-years of exposure: an integrated analysis of 3 clinical trials in adult patients with psoriatic arthritis

Published Date: January 21, 2020
Publication Link

Ixekizumab improves secondary lesional signs, pain and sexual health in patients with moderate-to-severe genital psoriasis

Published Date: January 9, 2020
Publication Link

Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial

Published Date: December 5, 2019
Publication Link

Candida Infections in Clinical Trials of Ixekizumab (Taltz), an Interleukin-17A Monoclonal Antibody, in Patients With Psoriasis or Psoriatic Arthritis

Published Date: December 1, 2019
Publication Link

Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure

Published Date: November 20, 2019
Publication Link

Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)

Published Date: November 5, 2019
Publication Link

Rapid Response of Biologic Treatments of Moderate-to-Severe Plaque Psoriasis: A Comprehensive Investigation Using Bayesian and Frequentist Network Meta-analyses

Published Date: November 4, 2019
Publication Link   |   Video Abstract Link

Ixekizumab sustains high level of efficacy and favourable safety profile over 4 years in patients with moderate psoriasis: results from UNCOVER -3 study

Published Date: October 29, 2019
Publication Link

Achievement of the National Psoriasis Foundation Treatment Targets With Ixekizumab: Pooled Analyses From Four Clinical Studies

Published Date: September 25, 2019
Publication Link

A 24-week multicentre, randomized, open-label, parallel-group study comparing the efficacy and safety of ixekizumab vs. fumaric acid esters and methotrexate in patients with moderate-to-severe plaque psoriasis naive to systemic treatment

Published Date: August 3, 2019
Publication Link

Absolute and Relative Psoriasis Area and Severity Indices (PASI) for Comparison of the Efficacy of Ixekizumab to Etanercept and Placebo in Patients with Moderate-to-severe Plaque Psoriasis: An Integrated Analysis of UNCOVER-2 and UNCOVER-3 Outcomes

Published Date: July 29, 2019
Publication Link

Translating Improvements with Ixekizumab in Clinical Trial Outcomes into Clinical Practice: ASAS40, Pain, Fatigue, and Sleep in Ankylosing Spondylitis

Published Date: June 28, 2019
Publication Link

Greater cumulative benefits from ixekizumab versus ustekinumab treatment over 52 weeks for patients with moderate-to-severe psoriasis in a randomized, double-blinded phase 3b clinical trial

Published Date: February 25, 2019
Publication Link

Prevalence and outcome of latent tuberculosis in patients receiving ixekizumab: integrated safety analysis from 11 clinical trials of patients with plaque psoriasis

Published Date: January 4, 2019
Publication Link

Impact of Ixekizumab Treatment on Itch and Psoriasis Area and Severity Index in Patients with Moderate-to-Severe Plaque Psoriasis: An Integrated Analysis of Two Phase III Randomized Studies

Published Date: November 21, 2018
Publication Link

Ixekizumab Improved Patient-Reported Genital Psoriasis Symptoms and Impact of Symptoms on Sexual Activity vs Placebo in a Randomized, Double-Blind Study

Published Date: November 15, 2018
Publication Link

Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1)

Published Date: November 1, 2018
Publication Link

Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial

Published Date: October 22, 2018
Publication Link

Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen-Week Results From a Phase III Randomized, Double-Blind, Placebo-Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors

Published Date: October 20, 2018
Publication Link

Blauvelt A, Gooderham M, Iversen L, et al. Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3).

Published Date: October 1, 2018
Publication Link

A statistical method to convert published response rates into marginal distributions with an example application in psoriasis

Published Date: September 26, 2018
Publication Link

Long-term safety profile of ixekizumab in patients with moderate-to-severe plaque psoriasis: an integrated analysis from 11 clinical trials

Published Date: September 10, 2018
Publication Link

Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitors

Published Date: September 7, 2018
Publication Link

Achieving minimal disease activity in psoriatic arthritis predicts meaningful improvements in patients’ health-related quality of life and productivity

Published Date: August 13, 2018
Publication Link

Points to consider for analyzing efficacy outcomes in long-term extension clinical trials

Published Date: July 26, 2018
Publication Link

Safety and efficacy of ixekizumab in patients with PsA and previous inadequate response to TNF inhibitors: week 52 results from SPIRIT-P2

Published Date: July 24, 2018
Publication Link

Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: Results from IXORA-S, a phase 3 study

Published Date: July 2, 2018
Publication Link

Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naïve patients with active psoriatic arthritis (SPIRIT-P1)

Published Date: June 25, 2018
Publication Link

Efficacy and safety of ixekizumab in patients with plaque psoriasis across different degrees of disease severity: results from UNCOVER-2 and UNCOVER-3

Published Date: June 12, 2018
Publication Link

Exposure-Response Modeling to Characterize the Relationship Between Ixekizumab Serum Drug Concentrations and Efficacy Responses at Week 12 in Patients With Moderate to Severe Plaque Psoriasis

Published Date: June 7, 2018
Publication Link

Minimal clinically important difference (MCID ) for work productivity and activity impairment (WPAI ) questionnaire in psoriasis patients

Published Date: May 30, 2018
Publication Link

Maintenance of skin clearance with ixekizumab treatment of psoriasis: Three-year results from the UNCOVER-3 study

Published Date: May 25, 2018
Publication Link

Ixekizumab Pharmacokinetics, Anti-Drug Antibodies, and Efficacy through 60 Weeks of Treatment of Moderate to Severe Plaque Psoriasis

Published Date: May 11, 2018
Publication Link

Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase III b study of patients with moderate-to-severe genital psoriasis

Published Date: May 10, 2018
Publication Link

Effect of psoriatic arthritis on ixekizumab clinical outcomes in moderate-to-severe psoriasis patients: A post hoc analysis

Published Date: March 28, 2018
Publication Link

Evaluation of sPGA × BSA as an Outcome Measure and Treatment Target for Clinical Practice

Published Date: March 23, 2018
Publication Link

Ixekizumab treatment shows a neutral impact on cardiovascular parameters in patients with moderate-to-severe plaque psoriasis: Results from UNCOVER-1, UNCOVER-2, and UNCOVER-3

Published Date: March 13, 2018
Publication Link

Efficacy and safety of continuous every-2-week dosing of ixekizumab over 52 weeks in patients with moderate-to-severe plaque psoriasis in a randomized phase III trial (IXORA -P)

Published Date: February 5, 2018
Publication Link

Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naïve patients with active psoriatic arthritis (PsA): results from SPIRIT-P1

Published Date: December 22, 2017
Publication Link

Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1)

Published Date: December 15, 2017
Publication Link

Matching-adjusted indirect comparison of efficacy in patients with moderate-to-severe plaque psoriasis treated with ixekizumab vs. secukinumab

Published Date: November 24, 2017
Publication Link

Infections from seven clinical trials of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriasis

Published Date: November 17, 2017
Publication Link

Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER -1, UNCOVER -2, UNCOVER -3)

Published Date: October 9, 2017
Publication Link

Impact of ixekizumab on facial psoriasis and related quality of life measures in moderate-to-severe psoriasis patients: 12-week results from two phase III trials

Published Date: October 6, 2017
Publication Link

Long-term Impact of Ixekizumab on Psoriasis Itch Severity: Results from a Phase III Clinical Trial and Long-term Extension

Published Date: September 20, 2017
Publication Link

Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3)

Published Date: September 14, 2017
Publication Link

Impact of Ixekizumab Treatment on Depressive Symptoms and Systemic Inflammation in Patients with Moderate-to-Severe Psoriasis: An Integrated Analysis of Three Phase 3 Clinical Studies

Published Date: September 14, 2017
Publication Link

Improvements in psoriasis within different body regions vary over time following treatment with ixekizumab

Published Date: August 9, 2017
Publication Link

Efficacy and safety of ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis: Subgroup analysis of a placebo-controlled, phase 3 study (UNCOVER-1)

Published Date: June 21, 2017
Publication Link

Impact of ixekizumab treatment on skin-related personal relationship difficulties in moderate-to-severe psoriasis patients: 12-week results from two Phase 3 trials

Published Date: June 2, 2017
Publication Link

Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial

Published Date: May 24, 2017
Publication Link

Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA -S, a phase III study

Published Date: May 19, 2017
Publication Link

What is clearance worth? Patients’ stated risk tolerance for psoriasis treatments

Published Date: May 12, 2017
Publication Link

The effect of bodyweight on the efficacy and safety of ixekizumab: results from an integrated database of three randomised, controlled Phase 3 studies of patients with moderate-to-severe plaque psoriasis

Published Date: May 4, 2017
Publication Link

Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate-to-severe plaque psoriasis and non-pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER -1, UNCOVER -2 and UNCOVER -3)

Published Date: March 26, 2017
Publication Link

Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis: Subgroup analysis of Latin American patients in the phase 3 randomized UNCOVER-3 studyComparación de ixekizumab y etanercept o placebo en la psoriasis de moderada a grave: análisis del subgrupo de pacientes latinoamericanos de la fase 3 del estudio aleatorizado UNCOVER-3

Published Date: March 23, 2017
Publication Link

Reaching complete or near-complete resolution of psoriasis: benefit and risk considerations

Published Date: March 16, 2017
Publication Link

Rapid improvements in health-related quality of life and itch with ixekizumab treatment in randomized phase 3 trials: results from UNCOVER -2 and UNCOVER -3

Published Date: March 10, 2017
Publication Link

Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis

Published Date: February 11, 2017
Publication Link

Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)

Published Date: January 10, 2017
Publication Link

Safety results of ixekizumab with 1822.2 patient-years of exposure: an integrated analysis of 3 clinical trials in adult patients with psoriatic arthritis

Published Date: January 21, 2020
Publication Link

A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial

Published Date: December 30, 2019
Publication Link

Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure

Published Date: November 20, 2019
Publication Link

A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial

Published Date: December 30, 2019
Publication Link

Prevalence and outcome of latent tuberculosis in patients receiving ixekizumab: integrated safety analysis from 11 clinical trials of patients with plaque psoriasis

Published Date: January 4, 2019
Publication Link

Long-term efficacy and safety of ixekizumab in Japanese patients with erythrodermic or generalized pustular psoriasis: subgroup analyses of an open-label, phase 3 study (UNCOVER -J)

Published Date: October 16, 2018
Publication Link

Long-term safety profile of ixekizumab in patients with moderate-to-severe plaque psoriasis: an integrated analysis from 11 clinical trials

Published Date: September 10, 2018
Publication Link

Infections from seven clinical trials of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriasis

Published Date: November 17, 2017
Publication Link

Can't find what you're looking for? Contact us for answers to your medical questions.

  • Copyright
  • Terms of Use
  • Privacy Statement
  • Accessibility Statement
  • Sitemap

    This site is intended for US Healthcare Professionals only.

    4.0.15 01/2023 | GLOOTH00001 04/2015 | © Lilly USA, LLC 2023. All rights reserved.

    Product names listed above are trademarks or registered trademarks owned by or licensed to Eli Lilly and Company, its subsidiaries, or affiliates

    facebook twitter linkedin
    visit www.phactmi.org
    Lilly